A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC
In this small phase 2 trial with limited sample size due to early termination, sitravatinib plus nivolumab demonstrated a manageable safety profile and produced modest clinical benefit. The observed responses occurred in patients who did not receive prior treatment with cabozantinib or lenvatinib. (ClinicalTrials.gov Identifier: NCT04904302).
Authors
- Eric Jonasch (ORCID: https://orcid.org/0000-0003-0943-2806)
- Matthew T. Campbell (ORCID: https://orcid.org/0000-0003-1915-4491)
- Amishi Y. Shah (ORCID: https://orcid.org/0000-0002-9007-0621)
- Ying Yuan (ORCID: https://orcid.org/0000-0003-3163-480X)
- Andrew Warren Hahn (ORCID: https://orcid.org/0000-0002-4153-205X)
- Nabil Adra (ORCID: https://orcid.org/0000-0001-8905-8329)
- Nizar M. Tannir (ORCID: https://orcid.org/0000-0001-5559-8060)
- Amado J. Zurita (ORCID: https://orcid.org/0000-0002-3805-7307)
- Lianchun Xiao (ORCID: https://orcid.org/0000-0003-0972-2766)
- Jianjun Gao (ORCID: https://orcid.org/0000-0001-6138-4472)
- Ulka N. Vaishampayan (ORCID: https://orcid.org/0000-0001-5800-4571)
- Pavlos Msaouel (ORCID: https://orcid.org/0000-0001-6505-8308)
- Nazlı Dizman (ORCID: https://orcid.org/0000-0002-3907-8513)
- Sagar S Mukhida
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Michigan (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf053
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Gateway for Cancer Research
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Regeneron Pharmaceuticals
- Exelixis
- Mirati Therapeutics
- Seagen
- Eisai
- Astellas Pharma
- Ipsen
- EMD Serono
- University of Texas MD Anderson Cancer Center